HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

HER2 peptide (369-377)

a component of an anti-HER2 vaccine

Also Known As:

E75 HER2 peptide; HER2 (369-377); nelipepimut-5; nelipepimut-S

Networked: 7 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
- Peptides: 82426
  - Peptide Fragments: 373
    - HER2 peptide (369-377): 7
Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Transferases: 6589
    - Phosphotransferases: 42769
      - Phosphotransferases (Alcohol Group Acceptor)
        Protein Kinases: 9677
        Protein-Tyrosine Kinases: 7697
        Receptor Protein-Tyrosine Kinases: 5999
        ErbB Receptors: 27986
        ErbB-2 Receptor: 526
        HER2 peptide (369-377): 7
Biological Factors: 2472
- Biomarkers: 240291
  - Tumor Biomarkers: 15272
    - ErbB-2 Receptor: 526
      - HER2 peptide (369-377): 7
- Antigens: 143924
  - Surface Antigens: 5813
    - Histocompatibility Antigens: 1132
      - Minor Histocompatibility Antigens: 395
        ErbB-2 Receptor: 526
        HER2 peptide (369-377): 7
  - Isoantigens: 1221
    - Histocompatibility Antigens: 1132
      - Minor Histocompatibility Antigens: 395
        ErbB-2 Receptor: 526
        HER2 peptide (369-377): 7

Experts

1.	Peoples, George E: 4 articles (01/2021 - 01/2014)
2.	Mittendorf, Elizabeth A: 3 articles (01/2021 - 01/2019)
3.	Alatrash, Gheath: 2 articles (01/2021 - 01/2020)
4.	Clifton, G Travis: 2 articles (01/2021 - 01/2020)
5.	Hickerson, Annelies T: 2 articles (01/2021 - 01/2020)
6.	Holmes, Jarrod P: 2 articles (01/2021 - 01/2020)
7.	Litton, Jennifer K: 2 articles (01/2021 - 01/2020)
8.	Murthy, Rashmi K: 2 articles (01/2021 - 01/2020)
9.	Qiao, Na: 2 articles (01/2021 - 01/2020)
10.	Vreeland, Timothy J: 2 articles (01/2021 - 01/2020)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/2020 - "Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data." 01/01/2020 - "Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer." 09/01/2014 - "We have conducted phase I/II clinical trials vaccinating breast cancer patients with nelipepimut-S and granulocyte-macrophage colony-stimulating factor (GM-CSF) in the adjuvant setting to prevent disease recurrence. " 01/01/2019 - "Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial." 09/01/2014 - "Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients."
2.	Triple Negative Breast Neoplasms 01/01/2021 - "Primary analysis of a phase IIb trial investigating the HER2-derived vaccine nelipepimut-S (NPS) did not benefit the intention-to-treat population, but subset analysis showed a benefit in triple-negative breast cancer (TNBC) patients. "
3.	Noninfiltrating Intraductal Carcinoma (DCIS) 01/01/2023 - "Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ."

Related Drugs and Biologics

1.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
2.	Vaccines
3.	lead sulfide (kohl)
4.	Trastuzumab (Herceptin)
5.	Protein Subunit Vaccines
6.	Proteins (Proteins, Gene)
7.	Peptides (Polypeptides)